Amicus Therapeutics, Inc. (FOLD) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $14.49 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away).
Amicus Therapeutics is a rare disease biotech with two approved products: Galafold (migalastat) for Fabry disease approved in 40+ countries generating $521.7 million in 2025, and Pombiliti plus Opfolda (cipaglucosidase alfa/miglustat) for late-onset Pompe disease generating... Read more
Sell if holding. Analyst target reached at $14.49 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $14.49 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $14.45. Score 5.7/10, moderate confidence.
Take-profit target: $14.21 (-1.9% upside). Prior stop was $14.45. Stop-loss: $14.45.
Analyst target reached - limited upside remaining; Near 52-week high (0.1% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9).
Amicus Therapeutics, Inc. trades at a P/E of N/A (forward 17.7). TrendMatrix value score: 6.2/10. Verdict: Sell.
14 analysts cover FOLD with a consensus score of 3.6/5. Average price target: $15.
What does Amicus Therapeutics, Inc. do?Amicus Therapeutics is a rare disease biotech with two approved products: Galafold (migalastat) for Fabry disease...
Amicus Therapeutics is a rare disease biotech with two approved products: Galafold (migalastat) for Fabry disease approved in 40+ countries generating $521.7 million in 2025, and Pombiliti plus Opfolda (cipaglucosidase alfa/miglustat) for late-onset Pompe disease generating $112.5 million in 2025. A definitive merger agreement with BioMarin at $14.50/share was signed December 19, 2025, expected to close Q2 2026.